Disrupting two established FOs, involving either a transcription factor, EWSR1-FLI1 (EF), in Ewing sarcoma, or a tyrosine kinase, BCR-ABL1 (BA), in chronic myeloid leukemia, resulted in efficient cancer cell death and reduced tumor burden and mortality [30]. The gene discussed is FLI1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.